Friday, September 14, 2007

Drug Companies Paying Docs To Over-Prescribe Psych Drugs

The New York Times found that psychiatrists who took the most money from makers of antipsychotic drugs tended to prescribe the drugs to children the most often. These and other stories have helped to fuel a growing interest among state and federal officials to document and restrict payments to doctors from drug makers.

A new federal bill called the "Physician Payments Sunshine Act of 2007" has been filed.

http://www.nytimes.com/2007/09/07/washington/07doctors.html?_r=2&ref=us&oref=slogin&oref=slogin

New York Times
Senators Seek Public Listing of Payments to Doctors

By GARDINER HARRIS
September 7, 2007

WASHINGTON, Sept. 6 — Makers of drugs and medical devices would be required to report publicly nearly all payments and gifts to doctors under legislation introduced Thursday in the Senate.

“Right now, the public has no way to know whether a doctor’s been given money that might affect prescribing habits,” said Senator Charles E. Grassley of Iowa, the ranking Republican on the Senate Finance Committee and one of the bill’s authors.

Senator Herb Kohl, Democrat of Wisconsin, said drug and medical device makers had long defended their payments and gifts to doctors as appropriate.

“If that is the case, full disclosure will only serve to prove them right,” Mr. Kohl said.

Ken Johnson, senior vice president at the Pharmaceutical Research and Manufacturers of America, said, “A new law is not necessary when pharmaceutical marketing is already heavily regulated by the Food and Drug Administration.”

The F.D.A. does not regulate the gifts or consulting arrangements drug and device makers routinely provide doctors, and it reviews only a fraction of the scripted marketing talks doctors make on companies’ behalf.

The bill results from growing concerns that free meals and consulting payments — which in some cases have exceeded $100,000 annually — lead doctors to prescribe more expensive drugs and devices, increasing the costs of health care and sometimes endangering patients.

Minnesota and Vermont require disclosures, and the legislatures of Maine and West Virginia have passed measures that may soon require them. Other states are considering similar measures.

The bill introduced Thursday is more comprehensive than any state measure. It includes medical device companies, not just drug makers, and has a more inclusive list of gifts and benefits that must be disclosed.

For instance, any payments or benefits made “directly, indirectly, through an agent, subsidiary or other third party” would have to be disclosed. That could include payments by universities and an array of small companies that, with industry financing, set up conferences for influential doctors at expensive hotels. Such payments have never been disclosed on a widespread basis.

The bill would also require the disclosure of financing for continuing medical education. Drug and device makers now underwrite much of the continuing education that is required of nearly all doctors.

Companies with at least $100 million in annual revenues would have to make quarterly disclosures of gifts or payments that exceed $25, and the reports would be posted on a Web site. Companies failing to make the disclosures — and many have not complied with the laws in Minnesota and Vermont — would be fined at least $10,000 per infraction.
Under the bill, the provision of free drug samples and financing for clinical trials would not have to be disclosed.

Rob Restuccia, executive director of the Prescription Project, a nonprofit group that works to eliminate conflicts of interest in medicine, said some academic medical centers already restricted gifts to faculty members. Greater disclosures would lead to more such restrictions, Mr. Restuccia said.


22,975 petition signatures against TeenScreen: http://www.petitiononline.com/TScreen/petition.html Video: http://www.youtube.com/watch?v=RfU9puZQKBY

Sunday, September 09, 2007

Message From AbleChild.org (Owen Wilson Data Included)

A Message From AbleChild.org:

We have learned that the Psychiatric and Drug Companies want to repeal the Black Box Suicide Warning that we all worked so hard to obtain. Trusting parents believed that placing their loved ones onto antidepressants was the right thing to do. No one ever told them about the deadly side effects of antidepressant-induced suicide. We only have to look at the recent Suicide Attempt of Owen Wilson, who was being treated with ANTIDEPRESSANTS to understand the fact that antidepressants are ineffective and dangerous. ("he did not overdose, "an attorney for Wilson told Access Hollywood. The attorney also said the actor did not have his stomach pumped. The attorney said Wilson had been taking antidepressants, but was not aware of any other drugs in his system at the time of the incident.). We need to ensure that the Black Box Warning remains on this product. We can no longer believe slanted studies paid for by those who profit from the very same product they are trying to sell. We question the findings of this study based on the fact that toxicity reports on the suicide victims were not release nor their medical records to indicate whether they were already using antidepressants. Take a moment for all suicide victims and take the vote. Should the Black Box be repealed or should it remain on the product?


A quick vote: Do you think the Drug Companies and Psychiatric Industry should be allowed to repeal the Black Box Warning. Vote Here

Thank you for all of your support and donations !

Respectfully,

Sheila Matthews
Co-Founder



Copyright 2001- 2007 Ablechild (Parents for Label and Drug Free Education). All rights reserved.
Ablechild is a nonprofit, tax-exempt, Section 501(c) (3) charitable organization,
and donations are deductible under the provisions of the IRS Tax Code.
Ablechild and the Ablechild logo is a Trademark of Ablechild, Inc.

Friday, September 07, 2007

The Truth About Increases In Suicide

There is a lot of "noise" running in the press about how suicides have gone up since the black box warnings for antidepressants were issued. It is total B.S.

The CDC (Center for Disease Control) reports an increase in youth suicide from 2003 to 2004 and some "experts" are blaming this increase on the decline in antidepressant use among youth. However, the Black Box Warning on SSRI-Class psychiatric drugs was not approved until September 2004, didn't go into affect until Jan/Feb 2005.

From Rosie Mysenberg (SSRI stories):

1) Across the country, the media are publishing an article concerning statistics on antidepressant use among youth in 2003 and 2004. They report a decrease in antidepressant use among youth and an increase in suicides. However, the report which came out from the American Psychiatric Association in 2004 reported an increase of 8% in antidepressant use among 19's and under. This statistic was for the first six months of 2004. [Note: the Black Box Warnings were not approved until September 2004]


2) Paragraph 11 reads: "In 2003, U.S. physicians wrote 15 million antidepressant prescriptions for patients under age 18, according to FDA data. In the first six months of 2004, antidepressant prescriptions for children increased by almost 8 percent, despite the new drug labeling." [Again, the Black Box Warnings were not approved until September 2004]


3) This is data from Medco Health Solutions, which manages pharmacy benefit programs. on 2005-2006. Notice the numbers.

http://www.webmd.com/parenting/news/20070517/prescription-drug-use-up-in-teen-girls

List of growth in prescription drug claims for 2001-2006 in girls and boys aged 10-19:

IT SHOWS ANTIDEPRESSANT RATES SINCE 2006 HAVE BEEN RISING NOT FALLING!

  • Attention deficit hyperactivity disorder (ADHD) drugs. Up nearly 74% for girls and 37% for boys
  • Antidepressants. Up more than 9% in girls and less than 1% in boys
  • Antipsychotics. Up more than 117% in girls and almost 71% in boys
  • Sleep aids. Up more than 80% in girls and about 64% in boys

Wednesday, September 05, 2007

Back To School: Pencils, Pens and Meds

Full story here: http://www.latimes.com/business/custom/admark/la-oe-klein20aug20,1,5517982.story?coll=la-headlines-business-advert
Los Angeles Times
August 20, 2007
Pencils, pens, meds
As kids head to class, pharmaceutical companies ramp up their drug marketing

Back-to-school season is in full swing. Time to pick out a backpack, sneakers and a stimulant medication for attention-deficit hyperactivity disorder.

Nearly 2 million children in the United States are diagnosed with ADHD...

Besides time off from school, many kids with ADHD get a summer "vacation" from the prescription medications...

Children in the U.S. are 10 times more likely to take a stimulant medication for ADHD than are kids in Europe.

The U.S., ...consumes about 85% of the stimulants manufactured for ADHD.

Sunday, September 02, 2007

More: Drug Companies Employ Ethics-Challenged Docs

The St. Petersburg Times exposed a couple of Florida psychiatrists today in an article entitled:
Who's judging drugs?
St. Petersburg Times
September 2, 2007
"You might think that when pharmaceutical companies hire a doctor to test new drugs, they automatically would reject someone disciplined for "gross or repeated malpractice." You would be wrong. A St. Petersburg Times analysis of public databases identified several doctors who have conducted clinical trials despite run-ins with the Florida Board of Medicine. "
Clinical trial - a process in which a medication or other medical treatment is tested for its safety and effectiveness

The Times wrote about:
Psychiatrist Serge Vilvar of North Miami Beach
Reprimanded, fined $50,000, suspended for 6 months, and put on a 1 year probation after the Florida Health Department found that he gave $3-million worth of unnecessary therapy to at least 14 patients. He worked on clinical trials after the Health Department initiated disciplinary action.

Psychiatrist Abbey Strauss of Boca Raton
Fined $15,000 for prescribing painkillers to a patient in excessive and inappropriate quantities which endangered the patient's health
Strauss has also conducted clinical trials after the Health Department initiated disciplinary action.

Thursday, August 30, 2007

A Note From Congressman Dan Burton

Parental consent for mental health screens

I am a co-sponsor of the “Parental Consent Act of 2007”(H.R. 2387) which seeks to essentially prohibit any student mental health screening program that allows mental health screening of individuals under 18 years of age without the express, written, voluntary, informed consent of the parent or legal guardian of the individual involved.

I appreciate the value of having mental health problems diagnosed and treated early but I have serious concerns about universal or mandatory mental health screening. I am worried that federally funded universal or mandatory mental health screening in schools without parental consent could potentially lead to labeling more children as “ADD” or “hyperactive” and thus force more kids into taking possibly dangerous psychotropic drugs, such as Ritalin, against their parents' wishes. Many children have already suffered harmful side effects from using psychotropic drugs. These side effects can include mania, violence, dependence, and weight gain. Furthermore, it is known that parents have been threatened by school districts with child abuse charges if they resist efforts to drug their children.

I know that some people believe that my concerns are overblown but I feel very strongly that parents' have a fundamental right to raise their children as they see fit and that includes making decision about evaluation and treatment of mental health conditions.

Indiana 5th District
Congressman Dan Burton

Wednesday, August 22, 2007

Plaintiffs Find Payday Elusive in Vioxx Cases

By ALEX BERENSON

http://topics.nytimes.com/top/reference/timestopics/people/b/alex_berenson/index.html?inline=nyt-per

KEENE, Tex. - In Carol Ernst's eyes, two years ago she won a measure of justice.

On Aug. 19, 2005, a Texas jury awarded Mrs. Ernst $253.5 million after concluding that Merck & Company and its painkiller Vioxx had caused the death of her husband, Robert, in 2001. At a news conference after the verdict, Mrs. Ernst said she was pleased that jurors had punished Merck for hiding Vioxx's heart risks. "This has been a long road," she said. "I just know that it was a road that I had to run and I had to finish."

But her comfort was premature. Merck, the third-largest American drug maker, appealed the verdict - which Texas laws on punitive damages automatically reduced to $26.1 million. Until higher courts rule on the appeal, Merck is not obligated to pay. So Mrs. Ernst, 62, has yet to receive any money.

In fact, none of the 45,000 people who have sued Merck, contending that they or their loved ones suffered heart attacks or strokes after taking Vioxx, have received payments from the company. The lawsuits continue, for now in a state of legal limbo, with little prospect of resolution.

In combating the litigation, Merck has made an aggressive, and so far successful, bet that forcing plaintiffs to trial will reduce the number of Vioxx lawsuits and, ultimately, its liability.

Promising to contest every case, Merck has spent more than $1 billion over the last three years in legal fees. It has refused, at least publicly, to consider even the possibility of an overall settlement to resolve all the lawsuits at once.

The strategy's successes, from the view of Merck and its shareholders, are clear. In the last year, the company has won most of Vioxx cases that have reached juries. Though its stock plunged immediately after the Robert Ernst verdict, it has since risen 80 percent, easily outpacing those of other big drug makers. And estimates of Merck's ultimate liability, once as high as $25 billion, are now closer to $5 billion, said C. Anthony Butler of Lehman Brothers .

The Merck executive most closely associated with the company's strategy, Kenneth Frazier, its general counsel, has prospered. In July, Mr. Frazier was promoted to president of the global human health division, where he oversees the marketing and sales forces, half of Merck's 60,000 employees.

When Merck withdrew Vioxx from the market in 2004, after a clinical trial found that the drug increased the risk of heart attacks when taken for 18 months or more, some predicted the company's doom. More than 20 million people in the United States had taken Vioxx, and some scientists estimated that as many as 100,000 might have suffered heart attacks. Merck said it had adequately warned patients and doctors of Vioxx's heart risks and that it never knowingly endangered patients.

The pace of Vioxx-related lawsuits, after soaring in 2005 and 2006, has fallen slightly this year, as plaintiffs' lawyers shy away from cases where they lack strong evidence that their clients took Vioxx for several months before having a heart attack. Lawyers have withdrawn several cases as they were about to go to trial.

"It seems to have worked quite well," Peter Schuck, a professor at Yale Law School who specializes in complex litigation, said of Merck's strategy. "They have discouraged the plaintiffs' bar from litigating these cases." The legal system is not set up to try thousands of cases at once, and nearly all Vioxx lawsuits are caught up in the pretrial process.

Plaintiffs' lawyers have tried to get the courts to combine all the potential suits into a single class action. But judges have rejected that tactic. Because the facts of individual cases can vary greatly, each case must be tried separately, courts have ruled.

So far, fewer than 20 Vioxx suits have reached juries, an average of 9 in each of the last two years. At this rate, the backlog of Vioxx cases will take years to work through and many plaintiffs may die before they get their day in court.

Even if they win, it will take years for plaintiffs to be compensated. Merck has appealed every case it has lost. In the case of Mrs.

Ernst, if her award is upheld, she will not be paid before 2010 at the earliest, her lawyer, W. Mark Lanier of Houston, said.

After the 2005 verdict, analysts wondered how Merck would overcome evidence presented in the case, showing that the company had been concerned about Vioxx's potential heart risks as early as 1997, two years before it began selling the drug.

"The possibility of increased C.V. events is of great concern," a Merck scientist, Dr. Alise Reicin, wrote in a 1997 e-mail message." "C.V. events" is medical shorthand for cardiovascular incidents like heart attacks. "I just can't wait to be the one to present those results to senior management," Dr. Reicin's message continued.

Other documents offered at the trial showed that in March 2000, Dr. Edward M. Scolnick, then Merck's top scientist, said a clinical trial had confirmed Vioxx's risks. Documents also showed that Merck resisted efforts at the Food and Drug Administration to add clear warnings to Vioxx's label.

Even after losing the Ernst case, Merck did not back down from its strategy of fighting every case. The company may have felt it had little choice, said Benjamin Zipursky, a law professor at Fordham University, who has followed the Vioxx litigation. Heart attacks are the most common cause of death in the United States, and more than 105 million Vioxx prescriptions were written in the five years before Merck stopped selling the drug. If it had not taken a hard line, Mr. Zipursky said, Merck would have faced an essentially unlimited pool of plaintiffs.

Merck has said it could not be certain that Vioxx caused heart attacks before seeing the results of a clinical trial in 2004. The company has also focused on making plaintiffs prove, with prescription records, that they took Vioxx continuously for months or years before a heart attack. It has also pointed out at trial that patients had other risk factors, like obesity or high cholesterol.

"We're continuing our strategy of looking at each case on the individual facts," said Theodore V. H. Mayer, a partner at Hughes Hubbard & Reed, the law firm coordinating Merck's defense. "Did they really have a heart attack? Did they really take the medicine? Did they take the medicine in proximity to the heart attack?"

Mr. Mayer said Merck was trying to clear the backlog of 45,000 cases. The company is moving through pretrial discovery - the process of learning the basic facts in a case - in 500 lawsuits in New Jersey alone, he said. The company faces 16,000 lawsuits in New Jersey.

Mr. Mayer said Merck had not yet found a single case where it believed that Vioxx caused a heart attack. Heart attacks are "a very, very common injury that occurs with or without medicine in many people," he said.

It is that attitude that infuriates the plaintiffs' lawyers. They say that since Merck has acknowledged that Vioxx can cause heart attacks in people who take it for more than 18 months, the company should be moving to settle some cases.

"Merck's goal is to manipulate the legal system to deprive justice to tens of thousands of people whose cases can never be heard," said Mr. Lanier, the lawyer who represented Mrs. Ernst. "Justice delayed is justice denied." He and other leading plaintiffs' lawyers say they will continue to pursue cases against Merck.

Robert J. Gordon, a partner at the law firm of Weitz & Luxenberg in New York, which represents about 3,300 Vioxx plaintiffs, maintains that pressure on Merck to reach a broad settlement may increase in 2008.

Judge Eldon E. Fallon in New Orleans, who is overseeing the 8,000 federal lawsuits filed against Merck, and Judge Carol E. Higbee in Atlantic City, who is overseeing state court suits in New Jersey, may be tiring of Merck's refusal to settle, Mr. Gordon said. "The courts are in the business of removing cases from their dockets," he noted.

But Mr. Schuck, the Yale law professor, said that plaintiffs might be disappointed if they think that pressure from judges will get Merck to settle. A faster trial calendar might actually benefit the company, which can coordinate its defense experts and trial teams more easily than the plaintiffs can, he said. And Merck's recent run of successes - it has won five of the last six cases and seven of the last nine, including one mistrial - has given it the upper hand, Mr. Schuck said. "Nobody can make them settle," he said.

Of course, the case against Vioxx is not settled either, and Merck's exposure continues. In the cases the company has lost, it has faced large damage awards. And it still faces the possibility of a class-action lawsuit from the insurers, states and other third-party groups that provided insurance coverage. The New Jersey Supreme Court, for instance, is considering whether a lawsuit should be allowed to proceed as a class action or whether different insurers should be forced to bring separate suits.

Several state attorneys general have sued the company, and federal prosecutors continue to investigate.

That leaves plaintiffs like Carol Ernst with little to do but wait."They could have all of their money and everything I own if they would just give him back to me," she said of her husband. "But they can't do that."

Copyright 2007

Saturday, August 11, 2007

The "Constant Gardener" Is Quite Real

If you haven't seen the film The Constant Gardener starring Rachel Weisz and Ralph Fiennes, be sure to rent it. If you have seen it, you know how it depicts the ruthless way in which major drug companies exploit third-world countries as guinea-pig areas for drugs, covering up their occasional disasters by paying off the right people to make the problem go away.

But here's a real-life version of the same thing: It's at http://www.physorg.com/news106016990.html

Here's part of the article:

Pfizer Facing 4 Court Cases in Nigeria

By HEIDI VOGT, Associated Press Writer
Anas Mustapha foreground  who was one of the children  tested with the meningitis epidemic  experimental drug and now suffering brain damage stands near the entrance of their house in Kano Nigeria Thursday July 19 2007 New York-based Pfizer is facing ...
Anas Mustapha foreground who was one of the children tested with the meningitis epidemic experimental drug and now suffering brain damage stands near the entrance of their house in Kano, Nigeria Thursday, July 19, 2007 New York-based Pfizer is facing four court cases two filed by the federal government , two by the state in Nigeria over a decade-old drug trial in the northern Muslim city of Kano. It is accused of using a 1996 meningitis epidemic to push through a sloppily managed study without the full understanding of the parents or the proper regulatory approval. AP Photo/George Osodi)

(AP) -- A security guard in this dusty Nigerian city is living with tragedy - a 14-year-old son whose dazed eyes, slow speech and uneven gait signal brain damage. Mustapha Mohammed says he knows who to blame - Pfizer Inc., the world's largest drug maker.
New York-based Pfizer is facing four court cases - two filed by the Nigerian government and two by officials in the northern Nigerian state where Mohammed lives - over a decade-old drug study that included Mohammed's son.

The company, which denies any wrongdoing, is accused of using a 1996 meningitis epidemic to push through a sloppily managed drug study that contributed to death in some and infirmities in others.

The fallout provides a case study of the ethical dilemmas that arise when Western medical priorities run into Third World poverty and ignorance. The communication gap between those handing out medical alms and those receiving has bred mistrust and anger in Kano - with damaging, far-reaching effect.

The Pfizer case was cited as one reason residents of Kano and the state of the same name boycotted a polio vaccine in 2003, fearing it was a plot to make Africans infertile. Polio exploded in Nigeria and eventually spread to 25 previously polio-free countries.

Though the meningitis epidemic is long over and the polio vaccination program is back on track, misinformation and suspicion persist.

READ THE REST AT THE LINK ABOVE...

Saturday, August 04, 2007

Lawmaker Calls for Registry of Drug Firms' Payments to Doctors

New York Times
Lawmaker Calls for Registry of Drug Firms Paying Doctors

By GARDINER HARRIS
August 4, 2007
WASHINGTON, Aug. 3 — An influential Republican senator says he will propose legislation requiring drug makers to disclose the payments they make to doctors for services like consulting, lectures and attendance at seminars.
The lawmaker, Charles E. Grassley of Iowa, the senior Republican on the Senate Finance Committee, cited as an example the case of a prominent child psychiatrist, who he said made $180,000 over just two years from the maker of an antipsychotic drug now widely prescribed for children.
Mr. Grassley is one of several lawmakers to propose a federal registry of such payments. Minnesota, Vermont and Maine already have similar registries, and other states are considering them.
The proposals are a response to growing concerns that payments from drug makers can affect doctors’ prescribing habits, increase the cost of health care and, in some cases, endanger patients’ health.
The drug industry opposes such registries, saying they would discourage doctors from receiving needed education. John Bentivoglio, a lawyer in Washington who represents drug makers, said the registries would be a burden for the companies and might be misinterpreted.
“One of the concerns is that these payments are seen as bribes,” Mr. Bentivoglio said. “That’s not the case. The vast majority are lawful payments for services.”

In a speech on the Senate floor on Thursday, Mr. Grassley said he had started an investigation into these practices. Noting that most universities require academic researchers to disclose such payments, he said, “I have sent letters to a handful of universities to understand how well such a reporting system actually works.”

These letters have uncovered several problems, Mr. Grassley said. First, universities do not verify the information filed by their professors, so “the only person who knows if the reported income is accurate and complete is the doctor who is receiving the money.”

Also, the universities generally keep this information secret from patients, who have no way of knowing whether their doctor is on a drug maker’s payroll, he said.

“So if there is a doctor getting thousands of dollars from a drug company — payments that might be affecting his or her objectivity — the only people outside the pharmaceutical industry who will probably ever know about this are the people at that very university,” he said.

Mr. Grassley said that he had asked how much the child psychiatrist, Dr. Melissa DelBello at the University of Cincinnati, made from AstraZeneca, the London-based drug giant that manufactures the antipsychotic Seroquel.

Dr. DelBello’s studies of Seroquel in children have helped to fuel the widespread pediatric use of antipsychotic medicines. Those studies were inconclusive, but she has described them as demonstrating that Seroquel is effective in some children.

Asked in a past newspaper interview how much she was paid by AstraZeneca to help market Seroquel, she had said, “Trust me, I don’t make very much.” Mr. Grassley said this week that her disclosure forms at the University of Cincinnati show she received $100,000 from AstraZeneca in 2003 and $80,000 in 2004. Dr. DelBello consults for seven other drug makers as well. She did not respond to requests for comment this week.

Richard Puff, a university spokesman, said he did not know how much Dr. DelBello made in combined payments from all eight drug makers. Asked if the institution did anything to verify its professors’ financial disclosures, he replied, “We do trust our faculty when they’re making these disclosures.”

Mr. Grassley said he would propose that drug makers make public any payments made to doctors who bill the federal Medicare and Medicaid programs, which would include nearly all doctors.

Noting that voters can easily look up the contributions made to elected officials, he asked, “Shouldn’t we hold doctors to similar standards?”

Thursday, August 02, 2007

Bill To Drug Pregnant Women! Help Stop It.

YOUR URGENT ACTION IS NEEDED on a bill quickly moving through Congress called "The Mother's Act" (H.R. 20) that calls for pregnant women to be screened for mental disorders and new mothers to be screened for "postpartum depression," resulting in their being prescribed dangerous antidepressants or other psychiatric drugs.
1) Click here: http://www.capwiz.com/cchr/issues/alert/?alertid=10099911 to make your voice heard!
2) Just put in your zip code, click on pre-written paragraphs of your choice and the letter will be directed to your US Congressman! If you are a mother, please let your Representative know this. The software makes it very fast and easy.
3) Please forward to your friends to do the same.

Tuesday, July 31, 2007

Russian activist says held in psychiatric clinic

From Reuters News Service

By Olesya Dmitracova

MOSCOW (Reuters) - A Russian opposition activist told Reuters on Tuesday from inside a psychiatric hospital that she was being held there against her will because she had blown the whistle on abuse in mental health care.

Larisa Arap of the anti-Kremlin group United Civil Front and her colleagues say she is a victim of a local vendetta by healthcare workers after she gave an account to a newspaper alleging patients at another psychiatric unit in the same region were beaten and raped.

The full details of the case are not known, but Arap's detention has caused an outcry among Kremlin opponents who say it echoes the Soviet practice of confining political dissidents in mental institutions to keep them quiet.

Sounding exhausted but coherent, Arap spoke to Reuters on a mobile telephone from the psychiatric ward near the city of Murmansk, on the edge of the Arctic Circle, where she has been since July 5.

She said her problems began when she went to see a doctor to get a certificate testifying she was in sound mental health -- a standard requirement in Russia for renewing a driver's license.

"She (the doctor) called the police. They kept me by force, then an ambulance was called, they bundled me in there and brought me here where I was beaten," Arap said on the telephone she had borrowed from a visitor.

"I feel unwell but I am trying to hold out. But my strength is dying away," Arap said.

Yelena Vasilyeva, a fellow opposition activist who has visited Arap in hospital, said doctors had forcibly injected Arap with drugs... This article continues here.

Sunday, July 29, 2007

Kids on drugs - by prescription

Read today's St. Petersburg Times article about kids on antidepressants.

People are starting to agree that the emperor has not clothes. In the last week, we saw Lindsey Lohan get out of a psychiatric-style drug rehab institution, and within 11 days she was up on charges for driving under the influence of alcohol and cocaine was found on her person.

Psychiatric solutions don't work.

Saturday, July 14, 2007

WSJ Says Backlash Against Antidepressants

http://online.wsj.com/article/SB118428285736265304.html?mod=googlenews_wsj

The Wall Street Journal Home Page

The Unmedicated Mind

Backlash against antidepressants is fueling new interest in alternative treatments.
By NANCY KEATES
July 13, 2007

From lobotomies with ice picks to early antidepressants that caused brain hemorrhaging, Americans have a complicated and ever-changing approach to treating mental illness. Now, spurred by the growing disenchantment with antidepressants, an increasing number of people are seeking treatment for depression, anxiety and eating disorders from naturopaths, acupuncturists and even chiropractors. At the same time, more traditional psychiatrists are incorporating massage and meditation in their practices.

The treatments go beyond needles and spinal manipulation. They include Emotional Freedom Techniques -- tapping on the body's "energy meridians" as the patient thinks about upsetting incidents -- and craniosacral therapy, which involves a gentle rocking of the head, neck, spine and pelvis. In cranial electrotherapy stimulation, a AA-battery-powered device sends mild electrical currents to the brain. (The procedure has its roots in ancient Greek medicine, when electric eels were used.) Clinicians are also prescribing supplements like omega-3 fatty acids, found in fish oil, or amino acids like L-theanine, found in green tea.

Sarah Spring had been in therapy with a psychiatrist and on the antidepressant Wellbutrin for four years to work through a childhood trauma, but felt she wasn't making any progress. So she went to a naturopath -- a practitioner trained in holistic therapy and alternative treatments like herbal medicine and nutrition. (They attend a four-year naturopathic school -- a bachelor's degree is a prerequisite -- but only 15 states license naturopaths.) After two sessions of Emotional Freedom Techniques, the tapping treatment that is meant to clear emotions and restore balance, Ms. Spring says she doesn't get the same shortness of breath and accelerated heart rate she used to. "It's remarkable," says the Portland, Ore., marketing manager, who just started to decrease her dose of Wellbutrin.

To address the growing interest from professionals, Harvard Medical School's Department of Continuing Education will have three classes on complementary and alternative medicine in psychiatry over the next year, up from one a year since the class was introduced in 2003. David Mischoulon, an assistant professor of psychiatry at Harvard, says doctors who have attended the class report that more patients are asking for alternative treatments -- due to the side effects of antidepressants, as well as a lack of response to the medication. Only about half of patients who take antidepressants respond, he says. "It is time to broaden the horizons," he says.

But there is no proof that many of these methods work for treating mental illness. One large study found Emotional Freedom Techniques were no more effective than a placebo, while evidence is limited for acupuncture and fish oil (thought to reduce some types of depression) in the treatment of mental health problems. Using herbal supplements with conventional medicine can be dangerous, psychiatrists say. "There are always snake oil salesmen," says Carolyn Rabinowitz, president of the American Psychiatric Association.

[Ronald Parks]
Psychiatrist Ronald Parks combines conventional and alternative medicine.

Traditional therapists worry that alternative treatments might sway patients to give up conventional treatments too quickly. "People with very little data often say, 'This works,' " says Philip Muskin, Chief of Consultation-Liaison Psychiatry at Columbia-Presbyterian Medical Center in New York. A psychiatrist and trained hypnotist, Dr. Muskin believes that wellness techniques like yoga, herbs and acupuncture can make people feel better psychologically. But he says alternative providers don't have adequate training to diagnose or treat severe mental-health disorders. "Many think if you get your liver and spleen into the right balance that will help," he says.

Safety Concerns

In any one-year period, 9.5% of the population, or about 20.9 million American adults, suffer from a mood disorder, according to the National Institute of Mental Health. A study by the World Health Organization, Harvard University School of Public Health and the World Bank found that by the year 2030, depression will be second only to HIV/AIDS in terms of disability caused world-wide.

A backlash against antidepressants sparked by concerns about their safety, efficacy and side effects is helping drive patients to alternative methods. Some 80% of antidepressants are currently prescribed by primary doctors who often diagnose depression in a 20-minute visit and don't provide accompanying therapy or help manage side effects.

Sales of all classes of antidepressants were $13.5 billion in 2006, down from a peak of $13.8 billion in 2004, according to IMS Health, a health-care information company. Usage of selective serotonin-reuptake inhibitors (SSRIs) dropped in 2005 after warnings about side effects -- particularly the risk of suicidal behavior in people aged 25 and under, which prompted the Food and Drug Administration to order drug makers to add warnings to their packaging in 2004. The introduction of generics onto the market (most recently, for Zoloft) also contributed to lower sales.

A spokesman for the Pharmaceutical Research and Manufacturers of America says pharmaceuticals like antidepressants undergo a rigorous assessment of benefits and risks by the FDA. Other methods have been used to treat depression historically, he says, but pharmaceuticals do and will continue to play a large role in therapy.

At the same time, the rise of managed care and changes in Medicaid and Medicare have resulted in companies paying far less for mental health coverage. Employer spending on mental health care dropped to 1.3% of an employee's medical care costs in 2006, from 10.9% in 1988, according to employee-benefits firm Towers Perrin. While most employees with health insurance have some mental-health coverage, only 13% have coverage for an unlimited number of outpatient visits to providers such as psychiatrists, psychologists and social workers, says a 2006 survey of employers by the Kaiser Family Foundation. That's down from 19% in 2004. Most insurance policies pay for a limited number of visits, often 20 or 30 per year, and some put a cap on the dollars they'll pay.

[Acupuncture]

Over the past decade, insurers have started covering more alternative procedures. Plans vary, from unlimited visits to 12 or 20 visits per year, according to Doug Metz, Chief Health Services Officer at American Specialty Health, which runs complementary medicine benefits plans for insurance companies. Co-payments typically run $10 to $20, and plans limit the reasons for visits to scientifically proven techniques -- which generally does not include treatments for mental health. While coverage for visits to naturopaths is mandated by law in Connecticut, Vermont and Washington, employers can still limit the number of visits and restrict it to a network.

Aetna, for one, will cover acupuncture used to treat migraine headaches or chronic lower back pain, but not for depression; it will cover biofeedback for migraines, but not stress. The options are growing: Starting this month, members can get at least 25% off standard fees for visits to an approved list of 19,000 credentialed "natural therapy professionals," including massage therapists and dietetic counselors, for any condition. (Standard fees for a first-time acupuncturist visit can be $90 to $120.)

The shift comes as scientific research sheds new light on the causes of depression. The use of SSRIs, introduced in the 1980s, aim to increase levels of serotonin in the brain. More recent research suggests that a range of factors -- including genetic predisposition and hormones linked to stress -- can play a role.

Proponents of alternative medicine say the wide range of treatments used address broader causes like hormonal imbalances and stress. Treatment can mean spending time talking to patients about their physical and emotional problems, examining their diet and exercise habits, and doing blood tests to look for medical or environmental causes for depression, such as Lyme disease, toxic chemicals or mold.

In Los Angeles, naturopath Holly Lucille has seen 30% more patients in the past two years whose chief complaint is mental-health-related, while Sara Thyr, a naturopath in Manchester and Concord, N.H., has seen a 20% rise. Margot Longenecker's naturopathy practice in Branford and Wallingford, Conn., now has half of its patients come for anxiety and depression, compared with 25% three years ago.

"Half the time you feel like you have a psychiatric degree more than a chiropractic degree," says Basking Ridge, N.J., chiropractor Jerry Szych, who's seen a 25% rise in patients seeking counseling services over the same period. Columbus, Ohio, chiropractor Ronald Farabaugh says he has seen an increase of 20% over the past three years in those cases.

Melissa Mannon, a 36-year-old photographer in Bedford, N.H., saw psychologists for years about her depression and anxiety. Then she visited a naturopath for help with infertility, and was diagnosed with an intolerance to 90 different foods, including gluten. She changed her diet and within seven months, she got pregnant and most of her anxiety and depression went away, she says. She still sees her naturopath if she's feeling down and to discuss what's happening in her life. "She understands me," says Ms. Mannon.

Some say the extra time and intimacy of the treatments can encourage patients to open up. Naturopath Mark Sanders, who has seen the number of patients coming for mental health rise threefold to about 60% since he started his practice five years ago, says patients tend to open up when he performs craniosacral therapy. (It is meant to ease stress and improve physical movement.) "I've had people tell me stuff they don't tell their therapist," he says.

[Samantha Brody]
'I don't dig into childhood stuff,' says naturopath Samantha Brody.

Stanford University Medical School clinical professor of medicine Kenneth Pelletier says chiropractors and naturopaths aren't adequately trained to recognize true psychopathology. But Dr. Pelletier believes most of these practitioners are ethical about remaining within the scope of their practice and refer patients to licensed mental-health-care practitioners when they think the diagnoses are severe.

That's what Portland, Ore., naturopath Samantha Brody has been doing as she increasingly sees patients with eating disorders, anxiety and depression. While the stigma of seeing a shrink may have declined in cities like New York and Los Angeles, it is alive and well in Portland, and some patients won't follow up on her referrals. Still, Ms. Brody steers away from serious counseling. "I don't dig into childhood stuff," she says.

Cheryl Higgins started seeing Ms. Brody three years ago for acupuncture because her back hurt. She was also driving her friends crazy by trying to use them as therapists and needed an outlet for her anxiety and depression. "I spilled my guts to her at the first session," says the 26-year-old office manager. Her treatment: chemical and amino-acid supplements, plus acupuncture three times a week.

Ms. Higgins hesitated to follow Ms. Brody's referral to a psychologist, but eventually she did see one who recommended that her primary care doctor put her on an antidepressant. She went on Lexapro for nine months, then went back to the naturopath to help her get off of it. "It made me yawn all the time," she says.

While the research is limited, some studies have shown promise in using alternative methods to treat mental illness. A recent study at Boston University School of Medicine and McLean Hospital in Belmont, Mass., showed a neurochemical response to the practice of yoga that's similar to neurochemical responses seen when people are treated with antidepressants.

Even pharmaceutical companies are starting to look at ingredients that have traditionally been part of natural medicine. Last year, Novartis bought the U.S. rights to a drug called agomelatine -- a melatonin-related agonist that is thought to influence mood in part through the sleep-wake cycle.

Of course, alternative medicine has been used for mental health issues for years. A 2001 study by Ron Kessler and David Eisenberg at Harvard Medical School found that among those with anxiety and or depression, more than half used alternative medicine therapies; among those who sought the treatment of a licensed conventional provider, two-thirds also used alternative medicine during the prior year. The perceived helpfulness of the alternative therapies was similar to the perceived helpfulness of conventional therapies.

Some critics say the growing interest is, in a sense, a step backwards. As people become frustrated with the shortcomings of new treatments, they become more inclined to try age-old therapies, regardless of whether they've been rigorously tested. The treatment of depression is "a constant succession of hyped theories and overall pathetically little progress," says John Horgan, director of the Center for Science Writings at the Stevens Institute of Technology in Hoboken, N.J.

Serious Applications

Now, community clinics are using the approach. The Mental Health Center of Greater Manchester, N.H. -- which combines traditional psychiatry with naturopathic treatments for seriously mentally ill patients -- received a two-year grant last summer from the New York-based Ittleson Foundation to promote the intermingling of naturopathy and psychiatry. "It's just a better way to approach the problem," says Ronald Parks, an internist and psychiatrist in Asheville, N.C., who uses alternative methods and was just approached to create a community-based model near his practice.

Aliza Sherman Risdahl agrees. She began experiencing uncontrollable rage, irritation and anxiety after the birth of her daughter. Though the 42-year-old Anchorage, Alaska, consultant was already seeing a therapist, she didn't want to go on antidepressants. She turned to a naturopath, who diagnosed her with overactive adrenal glands and suggested an amino acid to spray under her tongue.

Now she's no longer throwing dirty plates from the dinner table up in the air, screaming at her husband to "give me the baby, you can't keep her from me!" and running through the house slamming doors and cursing at him. "I am so grateful," she says.

Friday, July 13, 2007

Suicide Victims Are Soaked With Psych Drugs

New Study Adds to Heated Debate over
Suicide Risks of Antidepressants


May 28, 2007


Analysis Reveals Suicide Victims Have Psych Drugs in Blood Stream

The findings of a study presented at the annual American Psychiatric Association (APA) conference in San Diego and published in Psychiatric Times may incite another firestorm in the heated debate over the correlation between antidepressants and suicide.

The psychiatric watchdog group, Citizens Commission on Human Rights (CCHR), says that in spite of psychiatric vested interests downplaying the suicidal side effects of antidepressants, which they have known about for more than a decade and a half (see video), new evidence has forced psychiatrists to acknowledge a link between antidepressants and suicide.

The study, "Antidepressants and Suicide in Children and Adolescents in Virginia: Toxicology Findings," analyzed toxicology reports in "unnatural" deaths from the Virginia Medical Examiner's Office, and was presented to the APA last week.

Researcher Dr. Antony Fernandez and colleagues found that youth suicide victims were significantly more likely to have SSRI (Selective Serotonin Reuptake Inhibitor) antidepressants in their bloodstream than were victims of other unnatural deaths. SSRIs were found in the bloodstream of at least 56 of the Virginia youth suicide victims whose toxicology results were available-the suicides ranged from poisoning to hanging and gunshots.

These findings follow a 2004 warning by the Food and Drug Administration (FDA) that children and teens are twice as likely to experience "suicidal thoughts and behaviors" than they are on placebo. The APA has yet to acknowledge that eight recent adolescents committing homicide in school shootings were in fact under the influence of antidepressants-documented to cause mania, psychosis, depersonalization, and in some cases, "homicidal ideation."

Despite mounting evidence of a link between antidepressants and suicide/violence, psychiatrists indiscriminately prescribe the drugs to millions, based on subjective diagnoses made without any physical tests-such as blood tests, brain scans or X-rays-and try to obscure the dangerous side effects of the drugs in order to protect billions in profit from drug sales.

Psychiatrist David Brent, one of the researchers in a recent study published in the Journal of the American Medical Association that pushed that the "benefits" of antidepressants for kids trumped suicidal side effects, urged the FDA to moderate the black box suicide warning on antidepressants - - although many parents' rights activists say this warning is imperative in upholding their right to informed consent. Another leading psychiatrist, John Mann of Columbia University, further attempted to diminish the negative publicity on such profitable drugs by claiming, "The idea that antidepressants are responsible for suicides isn't supported by the data."

CCHR says human rights activists, parents, experts and others who have been insisting that the public be warned about the suicidal side effects of antidepressants are once again vindicated by this new study on SSRIs in suicide victims. Because these findings are so alarming, the Psychiatric Times published "action points"-in effect, suggestions on how psychiatrists can assuage parents' fears that may prevent them from purchasing the drugs for their children-including telling consumers that the study "represents an association rather than causation..." and that "These data and conclusions should be considered preliminary...."

The Citizens Commission on Human Rights is an international psychiatric watchdog group co-founded in 1969 by the Church of Scientology and Dr. Thomas Szasz, Professor of Psychiatry Emeritus, to investigate and expose psychiatric violations of human rights.

For more information, contact CCHR at 800-782-2878 or
email: laurie@cchrflorida.org.

Citizens Commission On Human Rights of Florida
1217 N. Ft. Harrison
Dunedin, FL 33755

Thursday, July 12, 2007

Nevada TeenScreen Pusher Up On Ethics Charges

The entire article is reproduced below. To see it in its original setting, click here.

July 11, 2007
by Joe Enge

As reported by Samantha Stone with KOH Radio this morning, 2 of the 4 charges Joe Enge with EdWatch Nevada filed against state board member Gary Waters in June of 2006 in trying to implement TeenScreen have been upheld to warrant a formal hearing with the Nevada Commission on Ethics in September. Waters is no longer a board member, his final term ended in December of 2006. Waters set up The Center for Health & Learning as a non-profit to implement TeenScreen. I questioned whether it is legal for a state board member to set up a non-profit and use Nevada Department of Education equipment and office.

TeenScreen is a highly controversial mental health screen that asserts it can identify students from the 5th to 12th grades who are suicidal. Critics nationally point out TeenScreen does more harm than good with their self-admitted 84% rate of false positives and makes end runs around the Protection of Pupil Rights Amendment without obtaining proper, positive consent from parents. You can read details about TeenScreen on my former EdWatch Nevada Web site at: www.campaignsitebuilder.com/templates/displayfiles1/Tmpl34.asp?id=19383.

Also available at http://www.edwatchnevada.com/ is one of the actual TeenScreen exams. Much to their chagrin, TeenScreen’s “super secret” exam is now public. The exam is listed under the heading of “Downloads.”

The two charges for setting up the non-profit were dropped. The Nevada Commission on Ethics came to the conclusion that it is legal for a non-profit, set up by a Nevada State Board of Education member, to use government equipment and offices. What’s legal is not always what’s right. I questioned also how this could be done without formal State Board of Education approval. They concluded the State Superintendent of Instruction, Keith Rheault, could do this on his own authority. They also concluded Waters did not make any money. $71,000 was awarded to the Center for Health & Learning, but he did not receive any of it.

My information shows Waters intended to start collecting money from a far larger federal grant of $1.2 million after he left office in December of 2006, the very reason he set up the non-profit. I suspect the publicity and scrutiny of my filing these Ethics charges in June of 2006 threw a monkey wrench into those plans. The federal $1.2 million grant has a table on page 29 showing a list of staff who will participate in the project with their role and level of effort. Waters is listed as director of the Center for Health & Learning and 100% FTE (full time equivalent). The center is also listed as a sub-grantee for funding. He can’t be convicted of his intentions once out of office since he was forced by these charges not to carry it out.

The Nevada Commission of Ethics did find just and sufficient cause exists to hold a hearing and render an opinion regarding whether Waters did not properly disclose his commitment, interests, or business relationship at the March, April, and June 2006 Nevada State Board of Education meetings at the time proposed standards for supplemental mental health and suicide were discussed, violating {NRS 281.501 (4)}. They also found just and sufficient cause exists to hear whether Waters acting on the same issues at these meetings violated {NRS 281.501 (2)}. The Nevada Commission on Ethics is scheduled to hear this matter on September 12, 2007 in Las Vegas at the Grant Sawyer State Building, room 4401.

Given it is legal in Nevada for non-profits to use government equipment and facilities, I think I will request an office in the Nevada Department of Education building in Carson City on behalf of EdWatch Nevada to better oversee their activities. I wonder what their reply will be.

+++
Joe Enge serves as an education analyst with NPRI, as chairman of EdWatch Nevada, and as a member of the Carson City School Board. Author of two world history textbooks, columnist for Liberty Watch Magazine, Joe was a high school teacher in Nevada from 1988 to 2006 and a Fulbright teacher to the former Soviet Union. He was named a Madison Fellow in 2005

Tuesday, July 10, 2007

Paxil Settlement On… You Tube;
July 10th, 2007
By Ed Silverman

In an unusual move, the Public Citizen advocacy group has posted a video on YouTube to alert parents to a $48 million settlement of a lawsuit concerning Glaxo’s Paxil antidepressant and side effects. The drugmaker was required to announce the settlement terms last October, but wasn’t to publicize that the terms were improved and simplified in April, the group notes.

Even without receipts, parents can recover up to $100, but any money that isn’t claimed prior to the August 31, 2007, deadline will revert back to Glaxo. Although it’s not clear, Public Citizen may be correct in noting this is the first time such a class-action settlement uses YouTube to publicize terms.

The video, which is just a minute and a half, resembles a public service announcment read by a news anchor, who says: “Now, $48 million is sitting in a fund waiting to pay back parents whose children were on Paxil before their 18th birthday.” You can visit www.paxilpayback.org

See here: www.paxilpayback.org


You are entitled to this money if:
• you live in the U.S. and
• you purchased Paxil or Paxil CR for someone under the age of 18.

If you qualify, you MUST fill out a claim form and mail it to the Paxil Pediatric Settlement Administrator in order to receive compensation. The claims must be received by August 31, 2007.


Saturday, June 30, 2007

Citizens Commission on Human Rights Newsletter

The Citizens Commission on Human Rights has been an energetic watchdog on the subject of psychiatric abuses for decades. They continue to grow in size and effectiveness. In tribute to their efforts I am publishing their latest newsletter here, in full. If the urge to help them overtakes you, or if you need their help, there is contact information in the newsletter.

Please feel free to forward this News Update to anybody who you think will be interested in this information.

Precedent setting reports released this week exposed financial conflicts of interest between the pharmaceutical and psychiatric industry. Other media reports came out exploiting the dangers of psychiatric drugs and pointed out the criminal behavior of professionals charged with the responsibility of administering care to their patients. This week's media reports included stories of fraud, negligence and abuse:

The New York Times ran an article entitled "Psychiatrists Top List in Drug Maker Gifts" showing that as states begin to require that drug companies disclose their payments to doctors for lectures and other services, a pattern has emerged: psychiatrists earn more money from drug makers than doctors in any other specialty. How drug company money is influencing psychiatrists and other doctors has become one of the most controversial issues in health care. For instance, the more psychiatrists have earned from drug makers, the more they have prescribed drugs such as Zyprexa to children, for whom the drugs are especially risky and mostly unapproved. Currently, there is no federal law requiring such disclosure of payments, only a few state laws. Senator Charles E. Grassley, Republican of Iowa stated, "A federal law requiring public disclosure of payments to doctors could be very effective if it was carefully monitored and consistently applied."
http://www .nytimes.com/2007/06/27/health/psychology/27doctors.html?ref=us

A Washington Post article on the same subject entitled, "Conflict Alleged in Drug Firms' Education Role," tied in the vested interests of the pharmaceutical industry using the annual American Psychiatric Association convention to illustrate how psychiatrists are entrenched in drug company money. The article states, "Last year's meeting of the American Psychiatric Association in Toronto, the field's biggest educational conference, reflects the extent of corporate sponsorship. In that meeting program, a voluntary listing of the financial ties to drug firms of the physicians who served as instructors covered 14 pages. Some instructors were sponsored by at least a dozen companies."
http://www.washingtonpost.com/wp-dyn/content/
article/2007/06/26/AR2007062601963.html

Indianapolis Star published an article, "Judge sets date for first Zyprexa trial," which reports that Eli Lilly may be facing its first trial this fall in personal injury lawsuits over its top selling antipsychotic drug Zyprexa. U.S. District Judge Jack Weinstein said he will try about 30 Zyprexa suits at one time. The article mentions that at least eight states have filed suit against Lilly and the company has paid out more than $1 billion to settle lawsuits relating to the adverse effects of Zyprexa.
http://www.indystar.com/apps/pbcs.dll/article?AID=/
20070623/BUSINESS/706230434/1 003/BUSINESS

Boston Globe published an article entitled "Backlash on bipolar diagnoses in children: MGH [Massachusetts General Hospital] psychiatrist's work stirs debate" about the heavy backlash against the psychiatric industry following the death of a 4-year-old girl named Rebecca Riley in Michigan last year from a combination of psychiatric drugs prescribed by her psychiatrist. The article points out the responsibility of "one of the world's most influential child psychiatrists," Joseph Biederman of MGH, in connection with Riley's death. Biederman's work helped fuel a surge in the number of children diagnosed with bipolar disorder over the past 15 years, and the psychiatrist who prescribed the combination of powerful drugs to the toddler has admitted that she was influenced by the work of Biederman and his assistant, Dr. Janet Wozniak. In the article, Dr. Lawrence Diller, a California behavioral pediatrician stated, "I find Biederman and his group to be morally responsible in part…he provided all the quote, 'scientific justification' to address a public health issue by drugging little kids."
http://www.boston.com/yourlife/health/diseases/
articles/2007/06/17/backlash_on_b ipolar_diagnoses_in_children/

An Associated Press article entitled "Psychiatrist indicted for fraud in Paxil trials" exposes the crimes of psychiatrist Maria Carmen Palazzo who was indicted by a federal grand jury on 55 counts of health care fraud and false documentation in connection with a clinical trial of Paxil in children and adolescents. Palazzo defrauded Medicare by submitting fraudulent invoices to a local hospital for services that she claimed to have rendered to patients in the psychiatric program there. The indictment also charges that Palazzo defrauded Medicare because it paid her over $653,000 she was not entitled to receive.
http://www.wdsu.com/news/13508696/detail.html

The Sunday Express (UK) ran an article entitled "NHS Spends Millions On Drug That Turns Children Into 'Drones'," about how the British National Health Service (NHS) is spending more than £1 million a month on Ritalin and writing almost 7,500 prescriptions a week for the mind-altering drug. Information obtained from the Freedom of Information Act show that the prescriptions will cost taxpayers about £12.48 million this year alone. The report comes after new figures reveal at least 11 deaths are being linked to Ritalin or similar drugs. The Sunday Express also reports that doctors link 73 blood disorder reactions, 39 heart disorders, and 80 stomach disorders as some of the side effects of Ritalin. Dr. Sami Timimi, an expert in child behavior, says that "We could be storing up big problems for this generation of youngsters."
http://www.express.co.uk/posts/view/10244/
NHS+spends+millions+on+drug+that+turns +children+into+'drones'

The Philadephia Inquirer published an article entitled "Another life lost on DHS's watch." This story is about a 17-year-old boy, named Omega Leach, who was sent to Chad Youth Enhancement Center outside Nashville, Tennessee. The Center is a mental-health facility for troubled teenagers approved by the city's Department of Human Services. Leach was sent there on June 3rd after stealing a car, and a month later he died after a physical confrontation with staff that used restraint procedures.
http://www.philly.com/inquirer/front_page/
20070624_Another_life_lost_on_DHSs_wat ch.html

The Independent (UK) ran an article entitled "Ministers in U-turn on shock therapy" about how the government is making amendments to its controversial "Mental Health Bill" which originally pushed for electroshock on minors. Because of overwhelming opposition against the bill from concerned organizations, the government has agreed to a series of compromises. One of the most important changes is curbing the use of electroshock on minors. These changes to the bill are considered an improvement, but it's still said to be "not fit for the 21st Century."
http://news.independent.co.uk/uk/politics/article2666412.ece


For decades, CCHR has fought to expose the dangers and fraud of the psycho-pharmaceutical industry despite the objections of vested interests that profit from keeping the truth concealed.


If you would like to make a donation to CCHR to assist with our public awareness campaigns, click here: https://www.cchr.org/donate

© 2007 CCHR. All Rights Reserved. CITIZENS COMMISSION ON HUMAN RIGHTS, CCHR and the CCHR logo are trademarks and service marks owned by Citizens Commission on Human Rights.


Tuesday, June 26, 2007

Letter to Editor Says It All


This is a letter to the editor of the Fort Wayne Indiana News-Sentinel in response to an article about TeenScreen:

---

The article, "Help to ensure happy, healthy kids," by Jennifer L. Boen, barely scratches the surface over the controversy of mental health screening. Before the author goes touting supposed benefits, the pitfalls need to be examined. Why? Because it's a child's life that hangs in the balance.

To date there has been no study or documentation that proves that screening "benefits children," and there is no scientific study that shows that "early intervention can also spare a life." But there is plenty of evidence showing otherwise.

Experts say there is no evidence to support that TeenScreen does anything other than guarantee that a large number of children will end up on drugs. In May, 2004, after an in-depth investigation, the United States Preventive Services Task Force issued a report with findings that said:

1. There is no evidence that screening for suicide risk reduces suicide attempts or mortality; 2. There is limited evidence on the accuracy of screening tools to identify suicide risk; 3. There is insufficient evidence that treatment of those at high risk reduces suicide attempts or mortality.

A 2006 study that investigated TeenScreen, said that mental health screening should be considered only investigational in nature, and the U.S. Substance Abuse and Mental Health Services Administration (SAMHSA) labels screening as "experimental."

According to another 2006 peer-reviewed study: "Simply Asking Questions Can Increase Risky Behaviors" - the title says it all.

Then of course, there is the matter of TeenScreen's 10-minute questionnaire, a survey that asks questions such as:

1. Have you often felt very nervous or uncomfortable when you have been with a group of children or young people - say, like in the lunchroom at school or at a party?
2. Have you often felt very nervous when you've had to do things in front of people?
3. Have you often worried a lot before you were going to play a sport or game or do some other activity?
4. Has there been a time when you had less energy then you usually do?
5. Has there been a time when you felt you couldn't do anything well or that you weren't as good-looking or as smart as other people?
6. Has there been a time when nothing was fun for you and you just weren't interested in anything?

Hmm, sounds like normal behavior and thoughts are being labeled as pathological.

The screening "tools" have an 84 percent false-positive rate, meaning that 84 percent of the children screened were falsely identified. The developer of TeenScreen says that the false-positive rate can overwhelm a school with the number of students identified and acknowledges that his screening tool "would deliver many who were not at risk for suicide, and that could reduce the acceptability of a school-based prevention program."

TeenScreen is set up to "arrange treatment" - their words. TeenScreen claims throughout their literature that "The TeenScreen Program makes no treatment recommendations," yet "treatment" is the long-term goal for TeenScreen, according to their director. The TeenScreen developer says, "The main role is to motivate the student and their parents to seek treatment and to connect the adolescent to a mental health service in their community."

There are ways to help our children but screening them for mental health is not one of them.

Susan Weibert